• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

INC Re­search and in­Ven­tiv Health come un­der Sy­neos Health brand in clos­ing chap­ter of CRO merg­er

8 years ago
Deals
Outsourcing

Biotech in­vestapalooza con­tin­ues with more ven­ture rounds for star­tups; Ova­Science cuts half of its work­force (again)

8 years ago
News Briefing

On a roll, Macro­Gen­ics al­lies with Roche on a bis­pe­cif­ic de­vel­op­ment cam­paign

8 years ago
R&D
Pharma

At­las builds its dream team and hands over $25M to launch a new ap­proach to gene ther­a­py

8 years ago
Startups
Cell/Gene Tx

What break? Sarep­ta vet Ed Kaye quick­ly piv­ots to the helm of an­oth­er biotech up­start with a $40M bankroll

8 years ago
People
Startups

No­var­tis backs eye drop mak­er in $20M round, meds to fill gap left by Eylea/Lu­cen­tis

8 years ago
Financing

BioN­Tech rais­es mam­moth $270M A round, near­ing $1B mark as in­vestors con­tin­ue a love af­fair with mR­NA

8 years ago
Financing

Pfiz­er lines up an $830M al­liance with Arv­inas on pro­tein degra­da­tion

8 years ago
Financing

Al­ler­gan ax­ing 1,000-plus jobs, prep­ping for a painful on­slaught of Resta­sis knock­offs

8 years ago
R&D
Pharma

Cel­gene and blue­bird make a 'break­through' on BC­MA-tar­get­ing CAR-T; An­oth­er can­cer drug biotech gar­ners $39M start­up ...

8 years ago
News Briefing

All in: Boehringer In­gel­heim more than dou­bles its ven­ture fund to €250M

8 years ago
Financing

Pfiz­er dou­bles down on Sang­amo’s zinc fin­ger tech, adding ALS to a mix of gene ther­a­py al­liances

8 years ago
R&D
Pharma

The gene ther­a­py pric­ing de­bate gets re­al as Spark sets $850,000 charge for its pi­o­neer­ing drug

8 years ago
Pharma
Cell/Gene Tx

Up­start Ex­pan­sion bags a $55M launch round to join the hunt for RNA-tar­get­ing small mol­e­cules

8 years ago
Startups

John Mendlein steps in to help fo­cus on the big pic­ture at a fast-grow­ing Mod­er­na

8 years ago
People

Bio­gen vet Jean-Paul Kress takes the reins at NY­C's Syn­tim­mune

8 years ago
People

A bet­ter ap­proach to growth fac­tors? Schol­ar Rock rais­es $47M on SMA promise

8 years ago
Financing

Mi­crosoft, Google back DNAnexus' Big Da­ta work with $58M; No­var­tis, Temasek back $50M round for Pear’s med apps

8 years ago
News Briefing

Chi­nese deal­mak­ing: SARI nabs Italy’s NMS Group for $362M; In­ovio re­tools deal with Apol­lo­Bio

8 years ago
China
Pharma

Star drugs like BM­S' Op­di­vo, As­traZeneca's Lyn­parza will get speedy OKs in Chi­na this year, new re­port pre­dicts

8 years ago
China
Pharma

Ex-Pfiz­er CEO's start­up Cen­trex­ion gets $67M for PhI­II painkiller

8 years ago
Financing
Startups

Cel­gene vet Bar­er lines up a $23M start­up round for next-gen I/O tech out of Johns Hop­kins

8 years ago
Financing

In an end-of-year IPO blitz, 4 biotechs pitch new of­fer­ings to­tal­ing $370M

8 years ago
Financing

The class of 2017's win­ners and losers: A year of 'non­stop sci­en­tif­ic achieve­ments' rais­es trou­bling is­sues

8 years ago
Special
Pharma
First page Previous page 1059106010611062106310641065 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.